The PERFORMANCE II Trial

IF 11.4 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS JACC. Cardiovascular interventions Pub Date : 2025-02-10 Epub Date: 2025-01-08 DOI:10.1016/j.jcin.2024.10.031
William A. Gray MD , D. Christopher Metzger MD , James Zidar MD , Sasko Kedev MD, PhD , Ivo Petrov MD, PhD , Peter Soukas MD , Elad Levy MD , William Bachinsky MD , J. Michael Bacharach MD , Piero Montorsi MD , Victor Novack MD, PhD , Alexandra Lansky MD , Ralf Langhoff MD
{"title":"The PERFORMANCE II Trial","authors":"William A. Gray MD ,&nbsp;D. Christopher Metzger MD ,&nbsp;James Zidar MD ,&nbsp;Sasko Kedev MD, PhD ,&nbsp;Ivo Petrov MD, PhD ,&nbsp;Peter Soukas MD ,&nbsp;Elad Levy MD ,&nbsp;William Bachinsky MD ,&nbsp;J. Michael Bacharach MD ,&nbsp;Piero Montorsi MD ,&nbsp;Victor Novack MD, PhD ,&nbsp;Alexandra Lansky MD ,&nbsp;Ralf Langhoff MD","doi":"10.1016/j.jcin.2024.10.031","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Several randomized clinical trials have shown that the composite endpoint of death, stroke, and myocardial infarction (MI) is equivalent between carotid artery stenting and carotid endarterectomy. However, the risk of minor stroke has been consistently higher with carotid artery stenting.</div></div><div><h3>Objectives</h3><div>The authors sought to evaluate the safety and effectiveness of a novel carotid stent system comprised of a stent, an adjustable integrated embolic filter and a postdilation balloon, in patients at elevated risk for adverse events from carotid endarterectomy.</div></div><div><h3>Methods</h3><div>PERFORMANCE II (Protection against Emboli during caRotid artery stenting using a 3-in-1 delivery system comprised oF a pOst-dilation balloon, integRated eMbolic filter, and A Novel Carotid stEnt II) was a prospective, multicenter, single-arm study. The primary endpoint was the composite of major adverse events defined as death, all stroke, and MI within 30 days of the procedure, plus ipsilateral stroke through 12 months.</div></div><div><h3>Results</h3><div>A total of 305 patients were enrolled at 32 centers in the United States and Europe. The mean age was 69.6 ± 7.5 years; 65.9% were male, and 20% were symptomatic. The mean lesion length was 19.1 ± 6.7 mm, and 34.5% of lesions were severely calcified. At 30 days, there were 4 minor strokes (1.3%), with no major strokes. There was 1 cardiac death on day 30, resulting in a stroke/death rate of 1.6% and a stroke/death/MI rate of 2.3%. The 12-month primary endpoint occurred in 2.8%; there were no major strokes, clinically driven target lesion revascularizations, stent thromboses, or neurological deaths. The 30-day all stroke plus ipsilateral stroke through 12 months rate was 1.8%.</div></div><div><h3>Conclusions</h3><div>The rate of major adverse events was extremely low, demonstrating the study system is a safe, effective, and durable treatment option for high-risk patients. (Protection against Emboli during caRotid artery stenting using a 3-in-1 delivery system comprised oF a pOst-dilation balloon, integRated eMbolic filter, and A Novel Carotid stEnt II [PERFORMANCE II]; <span><span>NCT04201132</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"18 3","pages":"Pages 367-376"},"PeriodicalIF":11.4000,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Cardiovascular interventions","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1936879824014675","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Several randomized clinical trials have shown that the composite endpoint of death, stroke, and myocardial infarction (MI) is equivalent between carotid artery stenting and carotid endarterectomy. However, the risk of minor stroke has been consistently higher with carotid artery stenting.

Objectives

The authors sought to evaluate the safety and effectiveness of a novel carotid stent system comprised of a stent, an adjustable integrated embolic filter and a postdilation balloon, in patients at elevated risk for adverse events from carotid endarterectomy.

Methods

PERFORMANCE II (Protection against Emboli during caRotid artery stenting using a 3-in-1 delivery system comprised oF a pOst-dilation balloon, integRated eMbolic filter, and A Novel Carotid stEnt II) was a prospective, multicenter, single-arm study. The primary endpoint was the composite of major adverse events defined as death, all stroke, and MI within 30 days of the procedure, plus ipsilateral stroke through 12 months.

Results

A total of 305 patients were enrolled at 32 centers in the United States and Europe. The mean age was 69.6 ± 7.5 years; 65.9% were male, and 20% were symptomatic. The mean lesion length was 19.1 ± 6.7 mm, and 34.5% of lesions were severely calcified. At 30 days, there were 4 minor strokes (1.3%), with no major strokes. There was 1 cardiac death on day 30, resulting in a stroke/death rate of 1.6% and a stroke/death/MI rate of 2.3%. The 12-month primary endpoint occurred in 2.8%; there were no major strokes, clinically driven target lesion revascularizations, stent thromboses, or neurological deaths. The 30-day all stroke plus ipsilateral stroke through 12 months rate was 1.8%.

Conclusions

The rate of major adverse events was extremely low, demonstrating the study system is a safe, effective, and durable treatment option for high-risk patients. (Protection against Emboli during caRotid artery stenting using a 3-in-1 delivery system comprised oF a pOst-dilation balloon, integRated eMbolic filter, and A Novel Carotid stEnt II [PERFORMANCE II]; NCT04201132)
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
PERFORMANCE II试验:一种新型颈动脉支架系统的前瞻性多中心研究。
背景:几项随机临床试验表明,颈动脉支架置入术和颈动脉内膜切除术的死亡、卒中和心肌梗死(MI)复合终点是相同的。然而,颈动脉支架置入术的轻度中风风险一直较高。目的:作者试图评估一种新型颈动脉支架系统的安全性和有效性,该系统由支架、可调节集成栓塞过滤器和扩张后球囊组成,用于颈动脉内膜切除术后不良事件风险升高的患者。方法:PERFORMANCE II(使用由扩张后球囊、集成栓塞过滤器和新型颈动脉支架II组成的三合一输送系统预防颈动脉支架置入期间的栓塞)是一项前瞻性、多中心、单臂研究。主要终点是主要不良事件的综合,定义为手术后30天内的死亡、全卒中和心肌梗死,以及12个月内的同侧卒中。结果:在美国和欧洲的32个中心招募了305名患者。平均年龄69.6±7.5岁;65.9%为男性,20%有症状。病变平均长度为19.1±6.7 mm, 34.5%的病变严重钙化。30天时,有4例轻微中风(1.3%),无大中风。第30天有1例心源性死亡,导致卒中/死亡率为1.6%,卒中/死亡/心肌梗死率为2.3%。12个月主要终点发生率为2.8%;没有重大中风、临床驱动的靶病变血运重建术、支架血栓形成或神经系统死亡。30天的全卒中加上12个月的同侧卒中发生率为1.8%。结论:重大不良事件发生率极低,表明该研究系统对高危患者是一种安全、有效、持久的治疗选择。使用由扩张后球囊、集成栓塞过滤器和新型颈动脉支架II组成的三合一输送系统保护颈动脉支架置入期间防止栓塞;NCT04201132)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
JACC. Cardiovascular interventions
JACC. Cardiovascular interventions CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
11.60
自引率
8.80%
发文量
756
审稿时长
4-8 weeks
期刊介绍: JACC: Cardiovascular Interventions is a specialist journal launched by the Journal of the American College of Cardiology (JACC). It covers the entire field of interventional cardiovascular medicine, including cardiac, peripheral, and cerebrovascular interventions. The journal publishes studies that will impact the practice of interventional cardiovascular medicine, including clinical trials, experimental studies, and in-depth discussions by respected experts. To enhance visual understanding, the journal is published both in print and electronically, utilizing the latest technologies.
期刊最新文献
REPLY Editorial Board Transcatheter Edge-to-Edge Repair for SAM-Related Mitral Regurgitation in Patients With HCM Coronary Plaque and Physiological Characteristics in ACS Risk Assessment According to Lesion Count Atrial Fibrillation and Tricuspid Regurgitation in Patients Undergoing Mitral Valve Transcatheter Edge-to-Edge Repair
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1